# Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

> **NCT04203316** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Enasidenib
- **DRUG:** Enasidenib Mesylate

## Key facts

- **NCT ID:** NCT04203316
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-14
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-10-03
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203316, "Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT04203316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*